Trial Profile
A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Cancer metastases; Malignant melanoma; Merkel cell carcinoma; Solid tumours
- Focus Therapeutic Use
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Feb 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 07 Feb 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.